Agilon Health (AGL) Earnings Analysis

Agilon Health (AGL) has no confirmed upcoming earnings date. Last quarter (2026-02-25) it missed with EPS -11.5 USD vs -6.75 USD est (-70.4%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -5.28.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AGL next report earnings?

No confirmed upcoming earnings date is currently scheduled for AGL. This page updates as the calendar is published.

AGL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-25-11.5 USD-6.75 USD-70.4%Miss
2025-08-04-0.25 USD-0.11 USD-127.3%Miss
2024-11-07-0.29 USD-0.1 USD-190%Miss
2024-08-05-1.75 USD-1.75 USD0%Beat

Beat rate: 1/4 (25%) over reported quarters with consensus data.

AGL valuation and analyst view

Trailing P/E-5.28
Trailing EPS-22.50057 USD
Price / book10.97
Dividend yield0.00%
Market cap1.97B
Analyst consensusHold (8 buy / 15 hold / 2 sell)
Avg price target78.2 USD

Related research pages

Frequently asked questions

When is Agilon Health (AGL)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for AGL. This page updates as the calendar is published.

Did AGL beat earnings last quarter?

In its 2026-02-25 report, AGL posted EPS of -11.5 USD versus a -6.75 USD estimate — a miss of 70.4%.

What is AGL's earnings track record?

Over the last 4 reported quarters with consensus data, AGL beat estimates 1 times (25%).

What is AGL's current P/E ratio and EPS?

AGL trades at a trailing P/E of -5.28 on trailing EPS of -22.500572323633953 USD.

What do analysts rate AGL?

Analyst consensus is "Hold" across 25 ratings (0 strong buy, 8 buy, 15 hold, 2 sell, 0 strong sell). Average 12-month price target: 78.2 USD.